FI109203B - Menetelmä oleellisesti puhtaan heterodimeerisen molekyylin sekä farmaseuttisen koostumuksen valmistamiseksi - Google Patents

Menetelmä oleellisesti puhtaan heterodimeerisen molekyylin sekä farmaseuttisen koostumuksen valmistamiseksi Download PDF

Info

Publication number
FI109203B
FI109203B FI933292A FI933292A FI109203B FI 109203 B FI109203 B FI 109203B FI 933292 A FI933292 A FI 933292A FI 933292 A FI933292 A FI 933292A FI 109203 B FI109203 B FI 109203B
Authority
FI
Finland
Prior art keywords
molecule
region
binding
domain
immunoglobulin
Prior art date
Application number
FI933292A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI933292A (fi
FI933292A0 (fi
Inventor
Alejandro A Aruffo
Jeffrey A Ledbetter
Peter S Linsley
Nitin K Damle
Jr H Perry Fell
Original Assignee
Squibb Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb Bristol Myers Co filed Critical Squibb Bristol Myers Co
Publication of FI933292A publication Critical patent/FI933292A/fi
Publication of FI933292A0 publication Critical patent/FI933292A0/fi
Application granted granted Critical
Publication of FI109203B publication Critical patent/FI109203B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70542—CD106
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FI933292A 1991-01-24 1993-07-21 Menetelmä oleellisesti puhtaan heterodimeerisen molekyylin sekä farmaseuttisen koostumuksen valmistamiseksi FI109203B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US07/645,522 US5709859A (en) 1991-01-24 1991-01-24 Mixed specificity fusion proteins
US64552291 1991-01-24
US9200616 1992-01-24
PCT/US1992/000616 WO1992012994A1 (en) 1991-01-24 1992-01-24 Mixed specificity fusion proteins

Publications (3)

Publication Number Publication Date
FI933292A FI933292A (fi) 1993-07-21
FI933292A0 FI933292A0 (fi) 1993-07-21
FI109203B true FI109203B (fi) 2002-06-14

Family

ID=24589356

Family Applications (1)

Application Number Title Priority Date Filing Date
FI933292A FI109203B (fi) 1991-01-24 1993-07-21 Menetelmä oleellisesti puhtaan heterodimeerisen molekyylin sekä farmaseuttisen koostumuksen valmistamiseksi

Country Status (18)

Country Link
US (1) US5709859A (ko)
EP (1) EP0568645B1 (ko)
JP (1) JP3394534B2 (ko)
KR (1) KR100259061B1 (ko)
AT (1) ATE195254T1 (ko)
AU (1) AU648398B2 (ko)
CA (1) CA2099779C (ko)
DE (1) DE69231333T2 (ko)
DK (1) DK0568645T3 (ko)
ES (1) ES2148173T3 (ko)
FI (1) FI109203B (ko)
GR (1) GR3034524T3 (ko)
IE (1) IE920202A1 (ko)
IL (1) IL100731A (ko)
NO (1) NO313241B1 (ko)
NZ (1) NZ241357A (ko)
WO (1) WO1992012994A1 (ko)
ZA (1) ZA92467B (ko)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6130202A (en) * 1990-07-20 2000-10-10 Bayer Corporation Antiviral methods
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
US7449186B1 (en) 1990-08-02 2008-11-11 Fred Hutchinson Cancer Research Center Methods of blocking the interaction between stromal cells and hemopoietic cells with anti-VCAM-1 antibodies
US5827670A (en) * 1990-08-02 1998-10-27 Fred Hutchinson Cancer Research Center Methods of isolating and detecting bone marrow stromal cells with VCAM-1-specific antibodies
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
AU694933B2 (en) * 1993-01-25 1998-08-06 Dana-Farber Cancer Institute, Inc. Chimeric L- and P-selectin by exchange of domains - uses thereof
US6991790B1 (en) * 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
DE69824039T2 (de) 1997-12-08 2005-08-18 Lexigen Pharmaceuticals Corp., Lexington Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
US6228590B1 (en) 1998-03-23 2001-05-08 Genentech, Inc. Method of selection for genes encoding secreted and transmembrane proteins
WO1999052562A2 (en) * 1998-04-15 1999-10-21 Lexigen Pharmaceuticals Corp. Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
AU4176200A (en) * 1999-03-26 2000-10-16 Wistar Institute, The Novel genetic suppressor elements and methods of making the same
JP2003530070A (ja) * 1999-05-19 2003-10-14 レキシジェン ファーマシューティカルズ コーポレイション Ｆｃ融合タンパク質としてのインターフェロン−αタンパク質の発現および搬出
US7067110B1 (en) * 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US6617135B1 (en) * 1999-08-09 2003-09-09 Emd Lexigen Research Center Corp. Multiple cytokine protein complexes
AU2154401A (en) 1999-11-12 2001-05-30 Merck Patent Gmbh Erythropoietin forms with improved properties
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
GB9929151D0 (en) * 1999-12-09 2000-02-02 Univ Cambridge Tech Peptide and polypeptide display
WO2001058957A2 (en) * 2000-02-11 2001-08-16 Lexigen Pharmaceuticals Corp. Enhancing the circulating half-life of antibody-based fusion proteins
EP1289552B1 (en) * 2000-05-19 2006-03-29 The Center for Blood Research, INC. Methods for treating hemostatic disorders by soluble p-selectin
MXPA02012734A (es) * 2000-06-29 2003-04-25 Merck Patent Gmbh Mejoramiento de las respuestas inmunes mediadas por la proteina de fusion anticuerpo-citocina, mediante tratamiento combinado con agentes mejoradores de la captacion de inmunocitocina.
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
MXPA03008031A (es) * 2001-03-07 2003-12-04 Merck Patent Gmbh Tecnologia de expresion para proteinas que contienen porcion de anticuerpo isotipo hibrida.
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
CN100503639C (zh) * 2001-05-03 2009-06-24 默克专利有限公司 重组肿瘤特异性抗体及其应用
AU2002356496A1 (en) * 2001-05-16 2003-04-01 Ceptyr, Inc. Dsp-18 dual-specificity phosphatase
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
US20040116333A1 (en) * 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
WO2003048334A2 (en) * 2001-12-04 2003-06-12 Merck Patent Gmbh Immunocytokines with modulated selectivity
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
ATE471946T1 (de) * 2002-12-17 2010-07-15 Merck Patent Gmbh Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
JP2008502317A (ja) 2003-12-30 2008-01-31 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング Ｉｌ−７融合タンパク質
WO2005063808A1 (en) * 2003-12-31 2005-07-14 Merck Patent Gmbh Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
AU2005203962C1 (en) * 2004-01-05 2012-11-08 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
US8298532B2 (en) 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
UY28886A1 (es) 2004-05-10 2005-12-30 Boehringer Ingelheim Int Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
NZ590478A (en) * 2004-05-11 2012-07-27 Abgenomics Cooperatief Ua Peptide motif Pro-Met-(Glu or Ser)-Ile used to identify a ligand which on binding an activated T-cell receptor induces apoptosis or cell death
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
ES2342964T3 (es) * 2004-12-09 2010-07-20 Merck Patent Gmbh Variantes de la interleucina-7 con inmunogenicidad reducida.
EP2298815B1 (en) * 2005-07-25 2015-03-11 Emergent Product Development Seattle, LLC B-cell reduction using CD37-specific and CD20-specific binding molecules
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
KR101571027B1 (ko) * 2006-06-12 2015-11-23 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 효과기 기능을 갖는 단일쇄 다가 결합 단백질
WO2009126944A1 (en) * 2008-04-11 2009-10-15 Trubion Pharmaceuticals, Inc. Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
EP2421896A1 (en) * 2009-04-22 2012-02-29 Merck Patent GmbH Antibody fusion proteins with modified fcrn binding sites
KR101632312B1 (ko) 2009-11-03 2016-06-21 삼성전자주식회사 항체 불변 영역에 특이적으로 결합하는 융합 단백질, 그의 제조 방법 및 이를 이용한 항체 분리 방법
US8895700B2 (en) 2010-02-18 2014-11-25 Janssen Biotech, Inc. Monkey homolog of human interferon omega
WO2011130533A1 (en) 2010-04-16 2011-10-20 Centocor Ortho Biotech Inc. Engineered plant cysteine proteases and their uses
US8394378B2 (en) 2010-09-27 2013-03-12 Janssen Biotech, Inc. Antibodies binding human collagen II
SG189475A1 (en) 2010-11-05 2013-05-31 Transbio Ltd Markers of endothelial progenitor cells and uses thereof
EP2718325A4 (en) 2011-06-13 2015-03-11 ABGENOMICS COöPERATIEF U A ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
SG10202002577XA (en) 2015-09-21 2020-04-29 Aptevo Res & Development Llc Cd3 binding polypeptides
WO2017066530A1 (en) * 2015-10-15 2017-04-20 Anthrogensis Corporation Natural killer cells and ilc3 cells and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5109123A (en) * 1988-06-14 1992-04-28 Dana Farber Cancer Institute Alteration of ability of soluble CD4 fragments to bind HIV
US5147637A (en) * 1988-06-07 1992-09-15 The Rockefeller University Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma
EP0606518B1 (en) * 1988-09-28 2003-07-30 Dana Farber Cancer Institute Intercellular adhesion molecules and their binding ligands
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
EP0585963A1 (en) * 1989-05-23 1994-03-09 Otsuka Pharmaceutical Co., Ltd. Monoclonal antibodies to CMP-170 antigen on activated endothelial cells
US6458360B1 (en) * 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules

Also Published As

Publication number Publication date
NO313241B1 (no) 2002-09-02
FI933292A (fi) 1993-07-21
NO932437D0 (no) 1993-07-05
IE920202A1 (en) 1992-07-29
NZ241357A (en) 1994-04-27
ATE195254T1 (de) 2000-08-15
KR100259061B1 (ko) 2000-07-01
DE69231333D1 (de) 2000-09-14
CA2099779A1 (en) 1992-07-25
NO932437L (no) 1993-09-17
EP0568645B1 (en) 2000-08-09
AU648398B2 (en) 1994-04-21
IL100731A (en) 1997-07-13
ES2148173T3 (es) 2000-10-16
IL100731A0 (en) 1992-09-06
JPH06505388A (ja) 1994-06-23
CA2099779C (en) 2002-03-19
US5709859A (en) 1998-01-20
FI933292A0 (fi) 1993-07-21
EP0568645A1 (en) 1993-11-10
EP0568645A4 (en) 1994-09-28
DK0568645T3 (da) 2000-09-18
WO1992012994A1 (en) 1992-08-06
JP3394534B2 (ja) 2003-04-07
KR930703008A (ko) 1993-11-29
AU1339192A (en) 1992-08-27
DE69231333T2 (de) 2001-01-18
GR3034524T3 (en) 2000-12-29
ZA92467B (en) 1992-09-30

Similar Documents

Publication Publication Date Title
FI109203B (fi) Menetelmä oleellisesti puhtaan heterodimeerisen molekyylin sekä farmaseuttisen koostumuksen valmistamiseksi
Diamond et al. A subpopulation of Mac-1 (CD11b/CD18) molecules mediates neutrophil adhesion to ICAM-1 and fibrinogen.
IE83565B1 (en) Mixed specificity fusion proteins
Podolsky et al. Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody.
Mazzone et al. Leukocyte CD11/CD18 integrins: biological and clinical relevance
Teixido et al. Role of beta 1 and beta 2 integrins in the adhesion of human CD34hi stem cells to bone marrow stroma.
Burkly et al. Signaling by vascular cell adhesion molecule‐1 (VCAM‐1) through VLA‐4 promotes CD3‐dependent T cell proliferation
Springer Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration
Damle et al. Vascular cell adhesion molecule 1 induces T-cell antigen receptor-dependent activation of CD4+ T lymphocytes.
Languino et al. Fibrinogen mediates leukocyte adhesion to vascular endothelium through an ICAM-1-dependent pathway
Bazil et al. Shedding of the CD44 adhesion molecule from leukocytes induced by anti-CD44 monoclonal antibody simulating the effect of a natural receptor ligand.
Issekutz Inhibition of lymphocyte endothelial adhesion and in vivo lymphocyte migration to cutaneous inflammation by TA-3, a new monoclonal antibody to rat LFA-1.
Lima et al. Immunophenotypic characterization of normal blood CD56+ lo versus CD56+ hi NK-cell subsets and its impact on the understanding of their tissue distribution and functional properties
TICCHIONI et al. Integrin‐associated protein (CD47/IAP) contributes to T cell arrest on inflammatory vascular endothelium under flow
Yan et al. Leukocyte recruitment into human skin transplanted onto severe combined immunodeficient mice induced by TNF-alpha is dependent on E-selectin.
Jääskeläinen et al. Migration of recombinant IL-2-activated T and natural killer cells in the intercellular space of human H-2 glioma spheroids in vitro. A study on adhesion molecules involved.
Bierer et al. T cell receptors: adhesion and signaling
Funaro et al. Stimulation of T cells via CD44 requires leukocyte-function-associated antigen interactions and interleukin-2 production
Laudanna et al. Ligation of members of the beta 1 or the beta 2 subfamilies of integrins by antibodies triggers eosinophil respiratory burst and spreading.
CA2220098A1 (en) Cd6 ligand
Kieffer et al. Uncoupling in the expression of platelet GP IIb/IIIa in human endothelial cells and K562 cells: Absence of immunologic crossreactivity between platelet GP IIb and the vitronectin receptor alpha chain
Springer Signals on endothelium for lymphocyte recirculation and leukocyte emigration: the area code paradigm
PT101148B (pt) Moleculas de fusao soluveis com especificidade de ligacao para as moleculas de adesao celulares
Kishimoto et al. Leukocyte adhesion, trafficking, and migration
Figdor et al. and Y. VAN KOOYK